Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|October 26, 2022
Dr. McKay on the shifting second-line paradigm in advanced renal cell carcinoma
Author(s)Urology Times staff
Rana McKay, MD, says that given the frontline shift from anti-VEGF monotherapy to immunotherapy doublets for advanced renal cell carcinoma, many of the studies informing the second-line setting have become “somewhat antiquated.”
Advertisement
Rana McKay, MD, discusses the evolving treatment paradigm in the second-line setting for advanced renal cell carcinoma now that immunotherapy has revolutionized the first-line approach. McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5